Recent trials have reported motor function stabilization in PD patients over a year following AAV–GDNF treatment, highlighting this gene therapy’s potential to provide durable benefits by enhancing the resilience of dopaminergic neurons [193,194]. The gene discussed is GDNF; the disease is Parkinson disease.